RemeGen Co. Ltd. Class A
688331
Rang in aandelen
#2384
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces,... RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors. The company was founded in 2008 and is headquartered in Yantai, the People's Republic of China.
Aandeelprijs
$14.50
Marktkapitalisatie
$8.12B
Verandering (1 dag)
-4.96%
Verandering (1 jaar)
8.62%
Land
CN
Handel RemeGen Co. Ltd. Class A (688331)
Categorie
Healthcare
Koersgeschiedenis voor RemeGen Co. Ltd. Class A (688331)
Hoogste slotkoers: $14.96 op 2026-10-01
Laagste slotkoers: $6.44 op 2022-03-01
Laagste slotkoers: $6.44 op 2022-03-01
Koersgeschiedenis van RemeGen Co. Ltd. Class A van 2022 tot 2026
Jaarlijkse koersprestatie
| Jaar | Prestaties |
|---|---|
| 2026 (TTM) | 33.52% |
| 2025 | 157.04% |
| 2024 | -48.44% |
| 2023 | -13.90% |
| 2022 | 0.00% |
Aandelenkoers van vergelijkbare bedrijven of concurrenten
| Bedrijf | Aandelenkoers | Verandering 1jr% | Land |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $758.21 | 7.77% |
CH
|
